Heart Failure With Reduced Ejection Fraction Clinical Trial
Official title:
Pharmacist-led Intervention for Optimal Heart Failure Medications: A Pilot Randomized Controlled Trial
The goal if this pilot randomized controlled trial is to determine the feasibility of conducting and guide the design of a definitive trial of a pharmacist-led, remotely-administered intervention to optimize medications for heart failure (HF) with reduced ejection fraction (HFrEF) as part of a multidisciplinary HF clinic. Both the intervention group and comparator group will receive usual care by the multidisciplinary HF clinic, including standard-of-care clinical pharmacy services. In addition to usual care, participants randomized to the intervention arm will receive co-management of medications by a dedicated study pharmacist with advanced training and expanded scope of practice, with the aim of achieving optimal medical therapy for HFrEF based on the 2021 Canadian Cardiovascular Society HF guidelines. The intervention will consist of 30-minute remote (telephone) encounters with a clinical pharmacist every 1-2 weeks with the aim of initiating or titrating ≥1 medication per encounter using standard protocols, for an intervention duration of up to 4 months.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | September 30, 2024 |
Est. primary completion date | July 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Provision of signed and dated informed consent form; 2. Stated willingness to comply with all study procedures and availability for the duration of the study; 3. Age =18 years; 4. Clinic diagnosis of HF with New York Heart Association (NYHA) functional class 1 to 3 at time of screening; 5. Left ventricular ejection fraction (LVEF) =40% on cardiac imaging performed within 6 months prior to enrolment; 6. Willingness to receive medications for the management of HFrEF; 7. Access to necessary resources for participating (telephone ± computer with internet access). Exclusion Criteria: 1. Already receiving target doses of sacubitril-valsartan, evidence-based beta-blocker and a mineralocorticoid receptor antagonist at time of screening; 2. Lying/sitting systolic blood pressure <90 mm Hg at time of enrolment; 3. Serum potassium =5.5 mmol/L at time of enrolment; 4. =2 measurements indicating estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 within 3 months prior to enrolment; 5. Being considered for heart transplant, durable mechanical circulatory support, or intravenous inotropes at time of screening; 6. Requiring diuretic dose greater than furosemide 80 mg equivalents or requiring the addition of a thiazide-like diuretic for more than 3 days at time of screening; 7. Felt by the multidisciplinary HF clinic team to be unsuitable for the trial (e.g. substance abuse and other psychological disorders, significant language barrier). |
Country | Name | City | State |
---|---|---|---|
Canada | St. Paul's Hospital | Vancouver | British Columbia |
Lead Sponsor | Collaborator |
---|---|
University of British Columbia | University of Alberta |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of recruitment | Composite of: Proportion eligible at pre-screening =50% of all HF clinic patients assessed based on inclusion criteria at pre-screening; Proportion eligible at screening =25% of all patients based on inclusion and exclusion criteria on screening; Mean recruitment =2 participants/week. |
Baseline | |
Primary | Feasibility of achieving rapid optimal medical therapy in intervention arm | Feasibility of optimizing HFrEF pharmacotherapy with study intervention, defined as =90% attainment of modified OMT score [acceptable] =5 at 3 months in intervention arm and =80% attainment of modified OMT score 8 [optimal] at 6 months in intervention arm | month 6 | |
Primary | Feasibility of patient-reported outcome measure (PROM) collection & participant retention | Composite of: Follow-up at 6 months complete in =90% at 6 months, =80% at 12 months, excluding deaths =90% completion of PROM questionnaires at months 3 and 6, and =80% completion at month 12 |
month 12 | |
Secondary | Optimization of HFrEF medications | Modified optimal medical therapy (OMT) score. Range 0 (worst) to 8 (best): suboptimal (0-4), acceptable (5-7), optimal (8). | month 3 | |
Secondary | Optimization of HFrEF medications | Modified optimal medical therapy (OMT) score | month 6 | |
Secondary | Optimization of HFrEF medications | Modified optimal medical therapy (OMT) score | month 12 | |
Secondary | Medication adherence | 5-item Medication Adherence Report Scale (MARS-5) | month 3 | |
Secondary | Medication adherence | 5-item Medication Adherence Report Scale (MARS-5) | month 6 | |
Secondary | Medication adherence | 5-item Medication Adherence Report Scale (MARS-5) | month 12 | |
Secondary | Medication adverse effects | Open-ended question about HF medications | month 3 | |
Secondary | Medication adverse effects | Open-ended question about HF medications | month 6 | |
Secondary | Medication adverse effects | Open-ended question about HF medications | month 12 | |
Secondary | Quality of life: 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) | month 3 | ||
Secondary | Quality of life: 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) | month 6 | ||
Secondary | Quality of life: 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) | month 12 | ||
Secondary | Treatment burden | Treatment Burden Questionnaire (TBQ) | month 3 | |
Secondary | Treatment burden | Treatment Burden Questionnaire (TBQ) | month 6 | |
Secondary | Treatment burden | Treatment Burden Questionnaire (TBQ) | month 12 | |
Secondary | Treatment satisfaction | Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) | month 3 | |
Secondary | Treatment satisfaction | Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) | month 6 | |
Secondary | Treatment satisfaction | Treatment Satisfaction with Medicines Questionnaire (SATMED-Q) | month 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Completed |
NCT03614169 -
Direct HIS-pacing as an Alternative to BiV-pacing in Symptomatic HFrEF Patients With True LBBB
|
N/A | |
Recruiting |
NCT05278962 -
HF Patients With LVADs Being Treated With SGLT2i
|
Phase 4 | |
Completed |
NCT04210375 -
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
|
Phase 1 | |
Not yet recruiting |
NCT06433687 -
Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients
|
||
Completed |
NCT05001165 -
Dashboard Activated Services and Tele-Health for Heart Failure
|
N/A | |
Active, not recruiting |
NCT03701880 -
Early Use of Ivabradine in Heart Failure
|
N/A | |
Recruiting |
NCT05650658 -
Left vs Left Randomized Clinical Trial
|
N/A | |
Not yet recruiting |
NCT06299436 -
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
|
||
Recruiting |
NCT05992116 -
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
|
||
Recruiting |
NCT05365568 -
Left Bundle Branch Area Pacing for Cardiac Resynchronization Therapy: A Randomized Study
|
N/A | |
Active, not recruiting |
NCT05204238 -
Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
|
||
Not yet recruiting |
NCT04420065 -
Effects of Preferential Left Ventricular Pacing on Ventriculoarterial Coupling and Clinical Course of Heart Failure
|
N/A | |
Terminated |
NCT03479424 -
Home Outpatient Monitoring and Engagement to Predict HF Exacerbation
|
||
Completed |
NCT02113033 -
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
|
Phase 2 | |
Recruiting |
NCT03209180 -
Immediate Release Versus Slow Release Carvedilol in Heart Failure
|
Phase 4 | |
Recruiting |
NCT05299879 -
Screening for Advanced Heart Failure IN Stable ouTpatientS - The SAINTS Study
|
||
Recruiting |
NCT05637853 -
Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction
|
||
Completed |
NCT03870074 -
CPET Predicts Long-term Survival and Positive Response to CRT
|
||
Recruiting |
NCT04590001 -
Effect of the MobiusHD® in Patients With Heart Failure
|
N/A |